Gaelreokseu Secures 42 Billion Won in Series B Funding, Bringing Total Investment to 68 Billion Won

Gaelreokseu, a new drug design artificial intelligence (AI) platform company, announced on the 10th that it has completed a Series B funding round worth 42 billion won. With this investment, the company’s cumulative funding has reached 68 billion won.

Gaelreokseu secured 21 billion won in Series A funding in 2022, which marked the beginning of full-fledged recognition of its technological competitiveness and enabled it to continue its research and development. Based on the R&D achievements and business performance accumulated since then, the company has successfully closed this Series B round, once again proving its technological prowess and growth potential. Investors participating in this Series B round include Yuanta Investment, Korea Development Bank, Intervest, a combination of Daily Partners and NH Investment & Securities, Pathway Investment, SL Investment, a combination of Encore Ventures and TKG Ventures, Sneak Peek Investment, Korea Investment & Securities, and Mirae Asset Securities. In particular, Intervest has continued to provide follow-on investments since the seed round, while Daily Partners and Pathway Investment have also joined as follow-on investors after the Series A round, reaffirming their confidence in the company’s technology and long-term growth potential.

Gaelreokseu

Sanggyun Kim, Executive Director at Intervest, said, “AI-driven new drug development and protein drug design are areas where it is difficult to build competitiveness in a short period of time, but Gaelreokseu has demonstrated exceptional technical depth from the seed stage, based on many years of accumulated research experience,” adding, “We decided to make consecutive investments through the Series A and B rounds after continuously confirming the advancement of its research outcomes and the sophistication of its technology.”

Gaelreokseu’s protein design AI technology is regarded as being at a global top-tier level, and the company is cited as one of the leading players worldwide in the field of de novo (from scratch) antibody design. De novo antibody design is a highly challenging area that requires designing entirely new amino acid sequences and structures to realize specific functions, and even globally, successful cases are extremely limited.

Recently, the company has rapidly advanced its technology by succeeding in securing antibodies with high binding affinity through only small-scale designs, achieving a design success rate hundreds of times higher than before. Backed by experimental and research infrastructure that can quickly validate AI-designed drug candidates, the precision and completeness of its new drug design AI platform are also continuously improving.

On the business side, Gaelreokseu is expanding its partnerships both domestically and internationally. The company has initiated its full-scale global expansion by signing a joint research agreement with global pharmaceutical company Boehringer Ingelheim, and is also jointly developing new drugs with leading Korean companies such as Celltrion, LG Chem, HanAll Biopharma, and Y-Biologics.

The funds secured through the Series B round will be strategically invested in core R&D areas, including: advancement of the AI platform technology, expansion of R&D infrastructure, recruitment of top talent, and preclinical validation of new drug candidates. Through this, the company plans to further enhance its technological competitiveness and pioneer new markets by achieving tangible new drug development outcomes even for challenging targets that have been difficult to address with conventional approaches, thereby strengthening its global competitiveness.

Chaok Seok, CEO of Gaelreokseu, said, “Protein drug design technology is an area whose importance is rapidly increasing across the entire new drug development process,” adding, “Among these, Gaelreokseu has demonstrated top-tier technological capabilities in the highly challenging field of de novo antibody design.” She continued, “Building on this investment, we will accelerate the advancement of our platform and the validation of our pipeline, generate meaningful business outcomes in the global market, and contribute to the development of more effective therapies.”

This content was produced with the assistance of AI translation services.